Pennsylvania is currently home to 3293 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Philadelphia, Pittsburgh, Hershey and Allentown. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Strict Versus Permissive Thresholds for Initiation of Pharmacotherapy in Gestational Diabetes (START 2)
NCT06419803
Recruiting
The aim of our study is to compare neonatal and maternal outcomes using different thresholds for the initiation and titration of pharmacotherapy for gestational diabetes (GDM). Our goal is to compare a Strict and permissive threshold. The Strict study arm target range will be 65-120 mg/dL, with time in range goal of 70%. The permissive study arm target range will be 65-140 mg/dL, with target time in range goal of 70%.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
11/19/2024
Locations: Thomas Jefferson University, Philadelphia, Pennsylvania
Conditions: Gestational Diabetes, Pregnancy Related
Register for Updates
Strict Versus Permissive Thresholds for Initiation of Pharmacotherapy in Gestational Diabetes
NCT06419777
Recruiting
The aim of our study is to compare neonatal and maternal outcomes using different thresholds for the initiation and titration of pharmacotherapy for gestational diabetes (GDM). Our goal is to compare a strict and permissive threshold. The strict threshold is defined as two abnormal values or more over a one-week period (two fasting values elevated, two of the same post prandial values elevated, or 1 fasting and 1 post prandial value elevated), whereas the permissive threshold is defined as 50% o... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
11/19/2024
Locations: Thomas Jefferson University, Philadelphia, Pennsylvania
Conditions: Gestational Diabetes, Pregnancy Related
Register for Updates
TEE 3D RV Assessment for SAVR, Mini AVR, and TAVR
NCT05804240
Recruiting
Three-dimensional echocardiography has become a gold standard to assess right ventricular (RV) function, and investigators plan to use 3D transesophageal echocardiography to assess RV function in 3 types of aortic valve replacement (AVR): surgical AVR (SAVR), mini-sternotomy AVR (mini AVR), and transcatheter AVR (TAVR).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/19/2024
Locations: Thomas Jefferson University, Philadelphia, Pennsylvania
Conditions: Right Ventricular Dysfunction
Register for Updates
Abatacept in Immune Checkpoint Inhibitor Myocarditis
NCT05335928
Recruiting
The primary aim is to test whether abatacept, as compared to placebo, is associated with a reduction in major adverse cardiac events (MACE) among participants hospitalized with myocarditis secondary to an immune checkpoint inhibitor (ICI). The primary outcome, MACE, is a composite of first occurrence of cardiovascular death, non-fatal sudden cardiac arrest, cardiogenic shock, significant ventricular arrythmias, significant bradyarrythmias, or incident heart failure.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/19/2024
Locations: Lehigh Valley Health Network, Bethlehem, Pennsylvania
Conditions: Myocarditis Acute, Cancer
Register for Updates
Daily Adaptive Radiation Therapy an Individualized Approach for Carcinoma of the Cervix
NCT05197881
Recruiting
This is a single-arm, prospective, multi-center clinical trial designed to demonstrate that adaptive radiotherapy for locally advanced cervical cancer will translate into a decreased rate of acute gastrointestinal toxicity compared with the historically reported rate for non-adaptive intensity modulated radiation therapy (IMRT). The timepoint for this assessment will be at week 5 of external beam radiotherapy (EBRT) and will use the Patient-Reported Outcomes version of the Common Terminology Cri... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
11/19/2024
Locations: Fox Chase Cancer Center, Philadelphia, Pennsylvania
Conditions: Cervical Cancer by FIGO Stage 2018
Register for Updates
Study to Evaluate the Efficacy, Immunogenicity, and Safety of RSVpreF in Adults.
NCT05035212
Recruiting
Efficacy Study: This randomized, double-blinded, placebo-controlled Phase 3 study is designed to assess the safety, immunogenicity, and efficacy of a single dose of RSVpreF in the prevention of LRTI-RSV in adults: * At a dose of 120µg. * In adults 60 years of age and older. * The duration of the study for each participant will be up to approximately 24 months. * The study will be conducted in the United States, Canada, Netherlands, Finland, Argentina, Japan and South Africa. Substudy A: This s... Read More
Gender:
ALL
Ages:
60 years and above
Trial Updated:
11/19/2024
Locations: Capital Area Research, LLC, Camp Hill, Pennsylvania
Conditions: Lower Respiratory Tract Illness
Register for Updates
Transcranial Direct Current Stimulation and Rehabilitation to Ameliorate Impairments in Neurocognition After Stroke
NCT04897334
Recruiting
The purpose of this study is to determine whether a non-invasive brain stimulation technique, transcranial direct current stimulation (tDCS), combined with traditional cognitive therapy will improve cognitive function in patients with subacute stroke.
Gender:
ALL
Ages:
Between 18 years and 90 years
Trial Updated:
11/19/2024
Locations: Penn Medicine Rehabilitation, Philadelphia, Pennsylvania
Conditions: Ischemic Stroke, Cognitive Impairment
Register for Updates
A Study of ZN-c3 in Women With Recurrent or Persistent Uterine Serous Carcinoma
NCT04814108
Recruiting
This is a Phase 2 study to evaluate the clinical activity and safety of ZN-c3 (azenosertib) in adult women with recurrent or persistent uterine serous carcinoma (USC).
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
11/19/2024
Locations: Temple University Hospital, Philadelphia, Pennsylvania
Conditions: Uterine Serous Carcinoma
Register for Updates
A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation
NCT04065399
Recruiting
Phase 1 dose escalation will determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of revumenib in participants with acute leukemia. In Phase 2, participants will be enrolled in 3 indication-specific expansion cohorts to determine the efficacy, short- and long-term safety, and tolerability of revumenib.
Gender:
ALL
Ages:
30 days and above
Trial Updated:
11/19/2024
Locations: University of Pennsylvania, Philadelphia, Pennsylvania
Conditions: Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Mixed Lineage Acute Leukemia, Mixed Phenotype Acute Leukemia, Acute Leukemia of Ambiguous Lineage
Register for Updates
Natural History Study of Homocystinuria Caused by Cystathionine Beta-Synthase Deficiency (ACAPPELLA)
NCT02998710
Recruiting
The purpose of the study is to characterize the clinical course of homocystinuria in pediatric and adult patients aged 1 to 65 years under current clinical management practices
Gender:
ALL
Ages:
Between 1 year and 65 years
Trial Updated:
11/19/2024
Locations: Travere Investigational Site (Enrolling 1 to <5 Year-olds Only), Philadelphia, Pennsylvania
Conditions: Homocystinuria Due to CBS Deficiency
Register for Updates
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
NCT02174549
Recruiting
This phase 1 study is to determine the optimal dose and tolerability of a hypoxia-activating agent, tirapazamine, when it is combined with embolization in liver cancer. Liver cancer patients who are Child-Pugh score A, suitable for embolization with tumor no more than 4 nodules are eligible. Tirapazamine will be given by intra-arterial injection before embolization. Treatment effect is evaluated by MRI based on mRECIST criteria. Repeat treatment is necessary only if disease progression. Dose esc... Read More
Gender:
ALL
Ages:
Between 20 years and 99 years
Trial Updated:
11/19/2024
Locations: University of Pennsylvania, Philadelphia, Pennsylvania
Conditions: Hepatocellular Carcinoma, Gastrointestinal Cancer Metastatic, Neuroendocrine Tumors
Register for Updates
Mucopolysaccharidosis I (MPS I) Registry
NCT00144794
Recruiting
The Mucopolysaccharidosis I (MPS I) Registry is an ongoing, observational database that tracks the outcomes of patients with MPS I. The data collected by the MPS I Registry will provide information to better characterize the natural history and progression of MPS I as well as the clinical responses of patients receiving enzyme replacement therapy, such as Aldurazyme (Recombinant Human Alpha-L-Iduronidase), or other treatment modalities. The objectives of the Registry are: * To evaluate the lon... Read More
Gender:
ALL
Ages:
All
Trial Updated:
11/19/2024
Locations: Children's Hospital of Philadelphia HUP Medical Genetics- Site Number : 840089, Philadelphia, Pennsylvania
Conditions: Mucopolysaccharidosis I (MPS I)
Register for Updates